AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The company is riding an unstoppable long-term trend: strong demand for lifesaving medicines.

Could AstraZeneca Help You Retire a Millionaire?

Ionis Pharma

AstraZeneca (AZN) closes its agreement with Ionis for jointly developing and commercializing eplontersen in the United States.

AstraZeneca (AZN) Closes Agreement for Eplontersen With Ionis

TOKYO, Japan & MUNICH, Germany--(BUSINESS WIRE)--T-DXd Type II Variation Application Validated by EMA for Patients with HER2+ Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen

Astrazeneca (AZN) closed at $57.64 in the latest trading session, marking a -0.76% move from the prior day.

Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know

Moderna

Novavax

Pfizer

Could these vaccine stocks be prime additions to your portfolio today?

Good Stocks To Buy Right Now? 4 Vaccine Stocks To Check Out

Pfizer, AstraZeneca, and Novavax will be important players in the next stages of the world's battle against the pandemic.

3 COVID Stocks to Fight Omicron

A three-dose course of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine is effective against the omicron coronavirus variant, data from an Oxford University lab study shows. Findings from the study, yet to be published in a peer-reviewed medical journal, match those from Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), which have also found a third dose of their shots works against omicron.

Oxford Lab Study Suggests AstraZeneca's COVID-19 Booster Works Against Omicron

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DESTINY-Lung04 Phase 3 Trial of ENHERTU Initiated in Patients with Previously Untreated HER2 Mutant Metastatic Non-Small Cell Lung Cancer

DESTINY-Lung04 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Mutant Metastatic Non-Small Cell Lung Cancer

Protection offered by a third dose of the vaccine against omicron was comparable to two-dose protection against Delta.

AstraZeneca Says Third Dose Provides Effective Protection Against Omicron

AstraZeneca PLC (LSE:AZN) said a third jab of its Vaxzevria vaccine significantly boosts levels of antibodies that combat the Omicron variant of the Coronavirus (COVID-19) virus. The FTSE 100 drugs giant cited data from independent investigators at the University of Oxford that indicated a third booster jab neutralised the Omicron variant to levels that were roughly similar to those observed after the second dose against the Delta variant.

AstraZeneca says independent study indicates efficacy of its COVID-19 vaccine against Omicron variant

Dow Jones Newswires: AstraZeneca says COVID-19 booster effective against omicron in study

The FDA accepts and grants priority review to AstraZeneca's (AZN) sBLA for Ultomiris for treating adults with generalized myasthenia gravis. A decision is expected in the second quarter of 2022.

AstraZeneca's (AZN) Ultomiris sBLA Gets FDA Priority Review

AstraZeneca said it has taken “preliminary steps” to create the variant-specific vaccine “in case it is needed.”

AstraZeneca Begins Work On Omicron-Targeted Vaccine

Amgen

Amgen (AMGN) and AstraZeneca's (AZN) Tezspire is the only biologic medicine approved by the FDA to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.

Amgen, AstraZeneca's Asthma Drug Tezepelumab Gets FDA Nod

GlaxoSmithKline

Regeneron Pharmaceuticals

Vir Biotechnology

We take a look at the data reported so far on antibody treatments by Regeneron (REGN), AstraZeneca (AZN) and Vir (VIR) amid the Omicron variant scare. The results have been mixed mostly.

Omicron Variant Puts COVID-19 Antibody Treatments in Focus

The FDA has approved AstraZeneca plc (NASDAQ: AZN) / Amgen Inc's (NASDAQ: AMGN) Tezspire (tezepelumab-ekko) as add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Tezspire was approved following a Priority Review by the agency and based on the PATHFINDER clinical trial program results.

AstraZeneca - Amgen's Tezspire Biologic Scores FDA Approval For Severe Asthma

AstraZeneca PLC (LSE:AZN)'s Saphnelo (anifrolumab) therapy has been recommended for marketing authorisation in the European Union (EU) as treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE). If approved, Saphnelo would be the first new treatment for SLE in Europe in more than a decade, the pharmaceuticals company said in a statement.

AstraZeneca's lupus treatment Saphnelo recommended for approval in the EU

AstraZeneca PLC (LSE:AZN) said its Tezspire drug, developed in collaboration with Amgen, Inc, has been approved in the US for treatment of severe asthma in patients older than 12 years. Tezspire (tezepelumab-ekko) was approved following a Priority Review by the US Food and Drug Administration (FDA) and based on results from the PATHFINDER clinical trial programme and the pivotal NAVIGATOR Phase III trial, in which Tezspire demonstrated superiority across every primary and key secondary endpoint in patients with severe asthma, AstraZeneca said in a statement.

AstraZeneca and Amgen's Tezspire approved in US for severe asthma

Astrazeneca (AZN) closed at $56.02 in the latest trading session, marking a -1.87% move from the prior day.

Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know

A buy has been reiterated by Citi brokers for AstraZeneca PLC (LSE:AZN) (AstraZeneca PLC (LSE:AZN)) on the back of the pharma's announcement that its Coronavirus (COVID-19) antibody combination, Evusheld, offers “neutralising activity” against the Omicron variant. The bank's target price is £105.00.

Citi recommends buy of AstraZeneca on the back of Evusheld announcement

A BUY has been reiterated by Citi brokers for AstraZeneca PLC (LSE:AZN) (AstraZeneca PLC (LSE:AZN)) on the back of the pharma's announcement that its Coronavirus (COVID-19) antibody combination, Evusheld, offers “neutralising activity” against the Omicron variant. The target price is £105.00.

Citi recommends BUY of AstraZeneca stock on the back of Evusheld announcement

AstraZeneca PLC (LSE:AZN) reported its long-acting antibody combination for the prevention of COVID-19, Evusheld, offers a “neutralising activity” against the Omicron coronavirus variant. The pharma said this shows promise for wider use of the therapy.

AstraZeneca says anti-body combination offers 'neutralising activity' against Omicron

New preclinical data released by AstraZeneca Plc (NASDAQ: AZN) shows that its long-acting antibody Evusheld (tixagevimab co-packaged with cilgavimab) works against the Omicron variant. The early data showed that pseudovirus testing of the full omicron variant spike against the AstraZeneca mAb combo adds to the growing body of preclinical evidence demonstrating that it "retains activity against all tested variants of concern to date.

AstraZeneca's COVID-19 Antibody Effective Against Omicron Variant

The stock price of AstraZeneca plc (NASDAQ: AZN) increased by 2.24% today. This is why it happened.

AstraZeneca Stock (AZN): Why The Price Increased Today

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces that AstraZeneca (LSE/STO/Nasdaq: AZN) has exercised its first license option for an Invir.IO™ oncolytic virus (OV) developed from their on-going OV collaboration. The exercise of this option for an OV, integrating an undisclosed transgene, will result in Transgene receiving an $8 million payment f

News for AstraZeneca Stock (AZN)